Fig. 1From: Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational studyStudy timeline, including epochs of interest. LAI new starts, LAI discontinuations and PP1 to PP3 switches were examined by month from January 2019 to December 2020. LAI, long-acting injectable antipsychotic; PP1, one-month paliperidone palmitate; PP3, three-month paliperidone palmitateBack to article page